t'	PH-1DC
QUERY CONTROL FORM	RTIS USE ONLY
Application No. 007, 07 Prepared by ()(()())	Tracking Number O dOO
Examiner-GAU WEDMOD-1617 Date	Week Date 82304
No. of queries	IFU -

ACKET

k. Print Claim(s)
I. Print Fig.

n. PTO-270/328

m. Searched Column

q. PTOL-85b

s. Sheets/Figs

r. Abstract

f. Foreign Priority

h. Microfiche Appendix

g. Disclaimer

i. Title

e. Domestic Priority	j. Claims Allowed	o. PTO-892	t. Other
SPECIFICATION	MESSAGE		•
a. Page Missing	Claims 4.9	1.10 + 14 are	withdrawn
b. Text Continuity	and not re	Florad Der	-CLM 5/210/04
c. Holes through Data		J	, -,
d. Other Missing Text	<u> </u>		
e. Illegible Text	DTD-1440	1: Please	either initial
f. Duplicate Text	OR line 4	hrough c	itations.
g. Brief Description	Copies	provided	for retenence.
h. Sequence Listing			
i. Appendix			
j. Amendments			
k. Other			
CLAIMS			
a. Claim(s) Missing			
b. Improper Dependency		****	0
c. Duplicate Numbers			Thankyon
d. Incorrect Numbering			initials
e. Index Disagrees	RESPONSE		
f. Punctuation			
g. Amendments			
h. Bracketing			
i. Missing Text			
j. Duplicate Text			_
k. Other			
			initials

a. Serial No.

d. PCT

b. Applicant(s)

c. Continuing Data



inder the Paderwork Radiation Act of 1895, the persons are required to respond to a categotion of information galaxs it contains a valid GAID compol member

Substitute for form 1449A/PTO		Co	emplete if Known			
		NFORMATION DISCLOSURE Application Number Continuation of 09/661.836		336		
		(use as many sheets as necessary)	Filing Date December 4, 2001 Control of the First Named Inventor James Ronald Lawter Group Art Unit			
		luse of many sivers as necessary			00	
					ा व्य	
		•	Examiner Name,			
Sheet		2 of 4	Attorney Docket Number	ORA 100/102 CON	in	
		1 - 1,				
		OTHER ART	NON PATENT LITERATURE DOCUM	ENTS	THE STATE OF	
Examiner's Initials"	Cite No.'	itam (book, magazine, journal,	n CAPITAL LETTERS), title of the article serial, symposium, catalog, etc.), date, p ublisher, city and/or country where publis	age(s), volume-issus number(s),	TI	
	1	BARKER, et al., "Oral care with vancomycus paste for ri (1995).	5	en di Sura Maria		
	V	CARTEE, et al., "Evaluation of GM-CSF mouthwash for 7(5):471-7 (1994).	ash for prevention of chemotherapy-induced mucositis: a randomized, double-blind, dose-ranging study," Cytokiaa			
٠,	1	CHI, at al., "Effect of granulocyte-macrophage colony-si eucovoria chemotherapy," <i>J. Cha. Docol.</i> 13(10):2620		eck cancer patients after cirplatin, fluorouracil,	and	
		CUTLER & SCHUBERT, "Patient factors affecting Hebic (1993).	bactes pylon eradication with triple therapy," Am	erican Journal of Gastroanterology 88(4):505	509	
	1	EPSTEIN & WONG, "The efficacy of Sucraffete suspens 28(3):693-98 (1994).	ion in the prevention of grad trucesitis due to rad	ation therapy,* Int. J. Radiat. Oncol. Biol. Phys.		
	V	EPSTEIN, et al., "Benzydamine hydrochloride in prevent Pathol. 62(2):145-8 (1986).	ion and management of pain in oral mucositis ass	ociated with radiation therapy," Oral Surg. Ora	I Med. Oral	
	1	EPSTEIN, et al., "Prevention of oral mucositis in radiation therapy: a controlled study with bearydamine hydrochlande rinse," Int. 1. Radiation Oncology Biol. Phys. 16(6):1571-5 (1989).				
	1	Essentials of Medicinal Chemistry John Wiley and Soas	loc., pp 512-517 (1976).	,		
		FACCHINI, et al., "Attivita di flunoxaprofene per uso te 41(12):609-614 (1989).	pico nelle vaginiti aspecifiche. Confronto con moc	Isciclina sollosalicilato," <i>Minerva Ginecologica</i>		
	./	FERRETTI, et al., "Control of oral mucositis and candid Bone Marraw Transplant 3(5):483-93 (1990).	asis in marrow transplantation: a prospective, do	uble-blind trial of chlothexidina digluconate ora	rinse,"	
55566C	٠,,,,	I and the second				
z'ısninax			Date:	1/25/02	~~~~	

*EXAMINER: Initial if reference consid	grad, whether or not citation is in conto:	mance with MPEP DUB. DIBW Hite through	I CITATION II UDI ILI COMPILIZIMISMES OIN INI
*EXAMINER: Initial if reference consid	erea, whether or not citation is in contor	mance with MPEP 609. Draw line throug	I CITATION II UDI ILI COMDITURINA GIRO IIO
*EXAMINER: Initial if reference consid	atea, mustuel of not citation is in coulor	wance with water one. I niew hue fulding	I CITATION II UDI ILI COMOMINIMA AND IO
		mance with MAEL ONE. DIEM HUR folding	Control is not in companying and in-
		wante Mitu MAES OAR" DIRM HUR fulding	Control is not the companion as any nor
		mance with MPEP 609. Draw line throug	damen it not in companying and in
		mance with MPEP 609. Draw line through	Claren ii not in epinomanca and iio
*EXAMINER: Initial if reference considered, include copy of this form to		mance with MPEP 609. Draw line throug	Catation is not in comparison and in-
		mance with MPEP 609. Disw line throug	I CITATION II HOT IN COMPINGUES SHE HO

Burden Hour Statement: This form is astimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

ORA 100/102 CON

¹ Unique cristion designation number ¹ See attached Kinds of U.S. Patent Documents. ¹ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japenese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ¹ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible: ⁴ Applicant to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO	c	amplete if Known
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	Continuation of 09/661,836
(use as many sheets as necessary)	Filing Date	December 4, 2001
	First Named Inventor	James Ronald Lawter
	Group Art Unit	
	Examiner Name /	
200000000000000000000000000000000000000	Attorney Docket Number	ORA 100/102 CON

		OTHER ART NON PATENT LITERATURE DOCUMENTS	
xaminer's Initials*	Cita No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, sérial, symposium, catalog, etc.), date, pagels), volume-issue number(s), publisher, city and/or country where published	T'
	J	FOOTE, et al., "Randomized that of a chlorhexidine mouthwash for alleviation of radiation induced mixositis." J. Clin Oncol. 12(12):2630-33 (1994).	•
		FRANCESCHI, et al.: "Solitary J pouch ulcer causing pouchitis-like syndrome," Diseases of the Colon and Rectum 28(8):515-517 (1986).	
and the second	1	LOPRINZI, et at., "Alleviation of cytotoxic therapy-induced normal tissue damage." Sem. Oncol. 22(2) Suppl. 3:95-97 (1995).	
		MITSCHER, et al., "Quinelone antimicrobial agents. 1. Versatile new synthesis of 1-alkyl-1.4-dihydro-4-oxo-3-quinolineca-boxylic acids," J. Med. Chem. 21(5):485-9 (1978).	
		ROTHWELL & SPEKTOR, "Palkation of radiation related mucositis," Special Care in Dentistry 10(1):21-25 (1990):	
		SCHENK, et al., "Controlled local delivery of tetracycline HCl in the treatment of perimplant mucosal hyperplasia and micosatis," Clinical Oral Implants Research 8(5):427-433 (1997).	
	1	SONIS, 1993b, "Orel Complications in Cencer Therapy," In: Principles and Practice of Oncology, De Vitta et al., eds., pp. 2385-2394 (J. B. Lippincott, Philadelphia).	
	J	Spàcial Care in Dentistry Jan. Feb, pages 21-25 (1990).	
	J	SPIJKERVET, et al., "Chlorhesidine inactivation by saliva," <i>Ocal Surg. Ocal Med. Oral Pathol.</i> 69(4):444-49 (1990).	
	J	VERDL, et al., "A double-band, randomized, placebo-controlled, cressover trial of pentacilyline for the prevention of chemotherapy-induced oral nuccesitis." Oral Surp. Oral Med. Oral Pathol. Oral Regiol. Endod. 80(1):36-42 (1995).	•

Examiner's		(Date	
= 1.01/-			// / / / / / /
Examiner's Signature Julium	^^	Considered	125/02
The state of the s			

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will very depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

ORA 100/102 CON

ATL1 #495286 v1

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that Issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.